Nuvation Bio Inc reports results for the quarter ended in September 30 - Earnings Summary

Nuvation Bio

07/11/2024 04:57

* Nuvation Bio Inc  NUVB.N  reported a quarterly adjusted
loss
of 15 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -9 cents.  The mean expectation of five analysts for the
quarter was for a loss of 13 cents per share. Wall Street
expected results to range from -18 cents to -8 cents per share.
    * Revenue was $727.00 thousand​; analysts expected zero. 
    * Nuvation Bio Inc's reported EPS for the quarter was a loss
of 15
cents​.
    * The company reported a quarterly loss of $41.12 million.
    * Nuvation Bio Inc shares had risen by 1.3% this quarter and
gained 53.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Nuvation Bio Inc
is $6.00 
This summary was machine generated from LSEG data November 7 at
04:57 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.13          -0.15          Missed
 Jun. 30 2024      -0.06          -0.15          Missed
 Mar. 31 2024      -0.10          -0.07          Beat
 Dec. 31 2023      -0.10          -0.06          Beat